Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
September 16 2022 - 11:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of September 2022
Commission file number: 001- 38041
SCISPARC LTD.
(Translation of registrant’s name into English)
20 Raul Wallenberg Street, Tower A,
Tel Aviv 6971916 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
SciSparc
Ltd. (the “Company”) hereby announces that the shareholders of the Company approved all of the Proposals brought before
the annual general meeting of shareholders held on September 15, 2022 (the “Meeting”), by the respective requisite
majority in accordance with the Israeli Companies Law, 5759-1999, and the Company’s articles of association, as described in the
Proxy Statement which was attached as Exhibit 99.1 to the Company’s Report of Foreign Private Issuer on Form 6-K, furnished to the
Securities and Exchange Commission, on August 11, 2022, and sent in connection with the Meeting.
This Report
on Form 6-K is incorporated by reference into the registration statements on Form F-3 (File No, 333-266047 ,
File No. 333-248670
and File No. 333-233417)
and on Form S-8 (File No. 333-225773)
of the Company, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is
submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
SciSparc Ltd. |
|
|
Date: September 16, 2022 |
By: |
/s/ Oz Adler |
|
|
Name: |
Oz Adler |
|
|
Title: |
Chief Executive Officer |
2
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Sep 2023 to Sep 2024